Non-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan.

Despite numerous advances in treatment options, advanced gastric cancer (AGC) remains a major public health issue and the leading cause of cancer-related deaths. Cisplatin is one of the most effective broad-spectrum anticancer drugs for AGC and a doublet combination regimen of either cisplatin-based or 5-fluorouracil (5FU)-based chemotherapy is generally used for treatment of patients with AGC. However, there is still no consensus on the best regimen for treating AGC. Recently, various new chemotherapeutic agents, including oral 5FU, taxanes, and irinotecan, have been identified as improving the outcomes for AGC when used as a single agent or in combination with non-platinum chemotherapy. Nonetheless, it is still unclear whether non-platinum-based chemotherapy is a viable treatment option for patients with AGC. Accordingly, this review focuses on the efficacy and tolerability of non-platinum-based chemotherapy for patients with AGC.

[1]  R. Xu,et al.  Platinum-Based Versus Non-Platinum-Based Chemotherapy as First Line Treatment of Inoperable, Advanced Gastric Adenocarcinoma: A Meta-Analysis , 2013, PloS one.

[2]  J. Pérez-Fidalgo,et al.  Current questions for the treatment of advanced gastric cancer. , 2013, Cancer treatment reviews.

[3]  Michael M Gottesman,et al.  Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes , 2012, Pharmacological Reviews.

[4]  Yanlei Ma,et al.  Capecitabine for the treatment for advanced gastric cancer: efficacy, safety and ethnicity , 2012, Journal of clinical pharmacy and therapeutics.

[5]  H. Kuwano,et al.  Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer , 2012, British Journal of Cancer.

[6]  N. Pavlakis,et al.  Management of advanced gastric cancer , 2012, Expert review of gastroenterology & hepatology.

[7]  Fenghua Wang,et al.  Phase 2 Study of Capecitabine and Irinotecan Combination Chemotherapy (Modified XELIRI Regimen) in Patients With Advanced Gastric Cancer , 2011, American journal of clinical oncology.

[8]  F. Pasini,et al.  The role of chemotherapy in metastatic gastric cancer. , 2011, Anticancer research.

[9]  J. Ajani,et al.  A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma. , 2011, Future oncology.

[10]  Woo Ick Yang,et al.  A randomized phase 2 study of docetaxel and S‐1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy , 2011, Cancer.

[11]  J. Sakamoto,et al.  Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer , 2010, Gastric Cancer.

[12]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[13]  T. Takayama,et al.  Recent advances in chemotherapy for advanced gastric cancer in Japan , 2010, Surgery Today.

[14]  M. Nishiyama,et al.  Docetaxel: its role in current and future treatments for advanced gastric cancer , 2009, Gastric Cancer.

[15]  A. Ohtsu,et al.  Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. , 2009, The Lancet. Oncology.

[16]  Y. Kodera,et al.  Paclitaxel chemotherapy for the treatment of gastric cancer , 2009, Gastric Cancer.

[17]  Yoon-Koo Kang,et al.  Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Y. Kakeji,et al.  Phase II study of weekly paclitaxel by one-hour infusion for advanced gastric cancer , 2008, Surgery Today.

[19]  J. Zaluski,et al.  Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Masahiro Takeuchi,et al.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. , 2008, The Lancet. Oncology.

[21]  A. Norman,et al.  Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2008, The New England journal of medicine.

[22]  J. Roh,et al.  A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status , 2007, British Journal of Cancer.

[23]  Y. Jeen,et al.  A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer , 2007, British Journal of Cancer.

[24]  S. Al-Batran,et al.  Chemotherapy for advanced gastric cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  H. Kuwano,et al.  Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer , 2006, British Journal of Cancer.

[26]  Kazuhiro Yoshida,et al.  Synergistic effects of docetaxel and S‐1 by modulating the expression of metabolic enzymes of 5‐fluorouracil in human gastric cancer cell lines , 2006, International journal of cancer.

[27]  J. Ajani.  Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers , 2006, Cancer.

[28]  S. Sohn,et al.  Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer , 2006, British Journal of Cancer.

[29]  N. Foster,et al.  Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  S. Park,et al.  Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil , 2006, Anti-cancer drugs.

[31]  Jeffrey W. Clark,et al.  A Phase II Trial of Irinotecan in Patients with Previously Untreated Advanced Esophageal and Gastric Adenocarcinoma , 2005, Digestive Diseases and Sciences.

[32]  Chiun Hsu,et al.  Phase II Study of Weekly Paclitaxel and 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin in the Treatment of Recurrent or Metastatic Gastric Cancer , 2005, Oncology.

[33]  Jin Young Park,et al.  Phase II Study of Docetaxel and Capecitabine in Patients with Metastatic or Recurrent Gastric Cancer , 2005, Oncology.

[34]  J. Zaluski,et al.  Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  D. Arsène,et al.  Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  S. Song,et al.  A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  Z. Siddik,et al.  Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.

[38]  M. Ducreux,et al.  Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial , 2003, British Journal of Cancer.

[39]  J. Ajani,et al.  Docetaxel-based chemotherapy in the treatment of gastric cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  T. Taguchi,et al.  A Pilot Phase II Study of Capecitabine in Advanced or Recurrent Gastric Cancer , 2003, Oncology.

[41]  D. Sargent,et al.  A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia , 2002, International journal of gastrointestinal cancer.

[42]  Y. Bang,et al.  Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. , 2002, Japanese journal of clinical oncology.

[43]  Y. Tanaka,et al.  Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  E. Van Cutsem,et al.  Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  A. Murad,et al.  Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen. , 1999, American journal of clinical oncology.

[46]  J. Ajani,et al.  Phase II study of Taxol in patients with advanced gastric carcinoma. , 1998, The cancer journal from Scientific American.

[47]  A. van der Gaast,et al.  5-fluorouracil and folinic acid in advanced adenocarcinoma of the esophagus or esophago-gastric junction area. Rotterdam Esophageal Tumor Study Group. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  J. Wanders,et al.  Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. , 1994, British Journal of Cancer.

[49]  M. Buyse,et al.  Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  J. Fourtillan,et al.  Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  T. Fleming,et al.  A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. , 1985, JAMA.

[52]  M. Ebert,et al.  A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  F. Farhat.  A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer , 2007, Medical oncology.

[54]  Y. Rustum,et al.  Synergistic antitumor activity of capecitabine in combination with irinotecan. , 2005, Clinical colorectal cancer.

[55]  T. Hickish,et al.  Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.